Biotech Values

[swampboots]

Disastrous for shareholders. But, in short, in my opinion, all a brave spirited attempt to move the science needle risking billions against all realistic short term odds to try to "cuddle" up to having complete sovereignty over the long term effectiveness of a drug like Todelvy. From my few previous open air links regarding latest solid tumor insights, there seems to be a resounding data progression pointing to new avenues of modifying previously failed drugs to become statistically more meaningful and material.